Aduro Biotech, Inc.
Aduro BioTech is a clinical stage cancer immuno-oncology company focused on the development of first-in-class technology platforms and products designed to stimulate robust and durable immune responses against cancer. Its lead product candidate, CRS-207, is currently being developed for pancreatic cancer and mesothelioma. In addition, Aduro is developing a pipeline of proprietary product candidates, including two product candidates in collaboration with Janssen Biotech targeting prostate and lung cancers.
In Foresite Capital's view, Aduro BioTech's approach to cancer immuno-therapy lends itself to combination therapy that could lead to broad based efficacy across multiple tumor types.